Bafilomycin B1, a plecomacrolide originally found to be produced by different Streptomyces species, has been shown to display activity against gram-positive bacteria and fungi. This compound is shown to be a potent and selective inhibitor of all V-ATPases. Studies have demonstrated that Bafilomycin B1 inhibits the osteoclastic proton pump in vitro. In addition, this compound has displayed a capacity to have concentration-dependent effects on neuronal cell viability. Bafilomycin B1 may also promote the accumulation of autophagic vacuoles and trigger Bax-dependent apoptosis.
1. Werner, G., et al. 1984. J. Antibiot. 37: 110-117. PMID: 6423597
2. Dröse, S., et al. 1997. J. Exp. Biol. 200: 1-8. PMID: 9023991
3. Farina, C. and Gagliardi, S. 2002. Curr. Pharm. Des. 8: 2033-2048. PMID: 12171517
4. Shacka, J.J., et al. 2006. Autophagy. 2: 228-230. PMID: 16874105
See how others have used Bafilomycin B1. Click on the entry to view the PubMed entry .
PMID: # 26230309 Cioffi, AG. et al. 2015. J. Am. Chem. Soc. 137: 10096-9.
PMID: # 23663353 Hwang, JY. et al. 2013. AMB Express. 3: 24.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.